BioCentury | May 30, 2017
Clinical News

Gilead’s HIV combo non-inferior in four Phase III trials

...nucleotide analog prodrug reverse transcriptase inhibitor. Gilead lost a penny on Tuesday, closing at $64.49. Alicia Parker bictegravir Emtricitabine tenofovir exalidex Gilead...
BioCentury | Apr 28, 2017
Clinical News

Tenofovir exalidex: Interim Ph IIa data

...HBV infection in an open-label, Thai Phase IIa trial showed that once-daily 100 mg oral tenofovir exalidex...
...NASDAQ:CMRX), Durham, N.C. ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), Edison, N.J. Product: Tenofovir exalidex ( TXL ) (formerly CMX157...
...Milestone: NA Jaime De Leon TXL Chimerix Inc. ContraVir Pharmaceuticals Inc. Viral DNA polymerase European Association for the Study of the Liver tenofovir exalidex...
BioCentury | Oct 24, 2016
Clinical News

CMX157: Phase I/IIa ongoing

...of a Thai Phase I/IIa trial comparing 5, 10, 25, 50 and 100 mg oral CMX157...
...from the 5, 10 and 25 mg CMX157 cohorts. ContraVir has exclusive, worldwide rights to CMX157...
...22, 2014). Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), New York, N.Y. Product: CMX157...
BioCentury | Jun 27, 2016
Company News

Ciclofilin, ContraVir Pharmaceuticals deal

...CPI-431-32 . ContraVir said CPI-431-32 might “someday” be used in combination with its HBV candidate CMX157...
...PPIA ) antagonist, could enter the clinic in 2017. ContraVir has exclusive, worldwide rights to CMX157...
BioCentury | Mar 28, 2016
Clinical News

CMX157: Phase I/IIa started

...ContraVir began a dose-escalation, Thai Phase I/IIa trial of once-daily oral CMX157 in 50 healthy volunteers...
...The single-blind, placebo-controlled Phase I portion will evaluate 5, 10, 25, 50 and 100 mg CMX157...
...portion, expected to start next quarter, will compare 5, 10, 25, 50 and 100 mg CMX157...
BioCentury | Dec 22, 2014
Company News

Chimerix, ContraVir Pharmaceuticals deal

...Chimerix granted ContraVir exclusive, worldwide rights to develop and commercialize HBV and HIV candidate CMX157...
...million for European approval. Chimerix is also eligible for royalties and additional commercial milestone payments. CMX157...
...antiviral agent tenofovir diphosphate. ContraVir CEO James Sapirstein said ContraVir plans to concentrate on developing CMX157...
BioCentury | Dec 19, 2014
Company News

ContraVir obtains HBV candidate, investment from Chimerix

...Chimerix Inc. (NASDAQ:CMRX) granted ContraVir Pharmaceuticals Inc. (OTCBB:CTRV) exclusive, worldwide rights to develop and commercialize CMX157...
...after Merck & Co. Inc. (NYSE:MRK) in May terminated its partnership to develop and commercialize CMX157...
...and the biotech said it did not plan to develop the compound on its own. CMX157...
BioCentury | May 26, 2014
Company News

Chimerix, Merck deal

...deal in which Merck received an exclusive, worldwide license to develop and commercialize the biotech's CMX157...
...decision following a pipeline portfolio assessment. The biotech said it will evaluate development opportunities for CMX157...
BioCentury | Aug 13, 2012
Strategy

Merck's new mark in HIV

...Inc. 's SPI-452 is in Phase I testing. New additions Last month's additions included Chimerix's CMX157...
...provide details about the program. As for CMX157, Chimerix President and CEO Kenneth Moch said CMX157...
...some nephrotoxicity, as noted in the warnings section of the drug's label. According to Moch, CMX157...
BioCentury | Jul 30, 2012
Company News

Chimerix, Merck deal

...Chimerix granted Merck exclusive, worldwide rights to HIV candidate CMX157 . Chimerix will receive $17.5 million...
...in milestones, plus royalties. The product has completed a Phase I trial in healthy volunteers. CMX157...
Items per page:
1 - 10 of 37